Phase 01 Clinical Trials

LMP和DCTD之间的合作负责开发 几种新的药效学试验，包括一种超灵敏的免疫荧光试验， γ H2 AX（DNA双链断裂检测器）在肿瘤组织活检，和ELISA 拓扑异构酶I和聚ADP-核糖聚合酶（PARP）。这些分析对于以下方面至关重要： PARP抑制剂与拓扑异构酶I联合应用的首次人体临床试验 抑制剂以及新的非喜树碱拓扑异构酶I抑制剂， 在NIH临床中心被激活。此外，与肿瘤内科的合作 分支促进了新型DNA甲基转移酶抑制剂的开发 氟脱氧胞苷与四氢尿苷联合使用，已生产的药物 供CCR研究。

The collaboration between the LMP and DCTD has been responsible for the development of several new pharmacodynamic assays, including an ultrasensitive immunofluorescence assay for gamma H2AX (DNA double strand break detector) in tumor tissue biopsies, and ELISAs for topoisomerase I and poly ADP-ribose polymerase (PARP). These assays have been essential for first in human clinical trials of PARP inhibitors in combination with topoisomerase I inhibitors as well as of novel, non-camptothecin topoismerase I inhibitors that have been activated in the NIH Clinical Center. In addition, collaborations with the Medical Oncology Branch have facilitated the development of the new DNA methyltransferase inhibitor fluorodeoxycytidine used in combination with tetrahydrouridine, drugs that have been produced by DCTD for study by the CCR.